-> Contact Us    -> Site Map   
  -> Search
ImmunoGen, Inc.

Company OverviewOur TAP TechnologyProduct PipelineInvestor InformationJoin Our Team
ImmunoGen, Inc.
Targeted Therapies for Cancer

ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Tumor-Activated Prodrug (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.

Product Pipeline

We reported new preclinical findings with our IMGN901 and IMGN242 product candidates at the AACR 2008 annual meeting.

-> Find out about more of our pipeline compounds...



TAP Technology

ImmunoGen’s Tumor-Activated Prodrug (TAP) technology can expand the potential of monoclonal, or manufactured, antibodies in the treatment of cancer.

-> Learn how it works...





built@zoomedia.com © 2008 ImmunoGen, Inc. | Privacy Policy | Usage Policy